The designers of heart disease trials should ensure that they recruit enough women to reveal reliably whether they are responding to the drugs in a different way from men, according to research published on line today (Tuesday, 2 August) in Europes leading cardiology journal, the European Heart Journal.
Women are under represented in most clinical studies, so the data and the results are less well documented for them, according to Dr Verena Stangl, senior author of the paper, who is from the Charité Hospital, Humboldt-University Berlin, Germany.
Dr Stangl, who is Professor of Cardiology (Molecular Atherosclerosis) at the hospitals Department of Cardiology, Angiology and Pneumology, said that although the percentage of women in studies of coronary heart disease had risen since the mid 1980s to reflect the prevalence of CHD in women, they were still under represented in trials involving coronary artery disease, arterial hypertension and heart failure.
"Because too few women participate in heart disease trials we are not sure whether they really benefit from some therapeutic strategies that have shown clinical benefit in trials conducted predominantly in men. So, we prescribe drugs to women adapted from evidence-based data obtained from studies conducted mainly in men and we do not really know whether we help or harm the female patients. Take one example: as we have no prospective data for digitalis in female patients, its unclear whether it is really linked to increased mortality among women or whether this increase is an effect only of an overdose, and therefore whether they would benefit from lower doses adapted to their weight."
Dr Stangl said women have historically been under-represented in trials. The main reason was probably because cardiovascular diseases have erroneously been perceived as male diseases. As most cardiovascular diseases tend to occur later in women, co-existing health problems and age limitations on trials have worked against their inclusion. Late diagnosis due to different and more ambiguous symptoms was another reason and, for women of child-bearing age, the risks of damaging a foetus if a woman became pregnant, led to exclusion.
Dr Stangls call for increasing the numbers of women in heart trials is backed in an editorial also published in EHJ on line today by specialists from the University of Pavia in Italy.
Senior author Dr Silvia Priori, Associate Professor of Cardiology at the University of Pavia, said that research published this year showed that of 300 new drug applications to the US Food and Drug Administration (FDA) between 1995 and 2000 only 163 included an analysis according to gender. Yet 11 of the drugs involved showed a difference in the way a womans body dealt with the drugs compared with a mans (the pharmacokinetics).
"These differences underlie the importance of studying women as well as men in major cardiovascular trials. Most of the progress in this direction has occurred in the USA as a direct consequence of the commitment of funding agencies that have provided economic support only when a balanced gender presence was assured in the design of a trial," said Dr Priori.
She urged scientific societies to play a major role in ensuring trials investigate gender- specific response to therapy. The Europe Society of Cardiology (ESC), which publishes the European Heart Journal, recently developed the Women at Heart programme to organise initiatives targeted at promoting research and education in cardiovascular disease in women.
The ESC Congress in Stockholm (3-7 September) will focus specially on women and cardiovascular diseases, said Dr Priori, and the ESC is to perform gender-based analyses of data in the Euro Heart Survey – the programme that monitors clinical practice in Europe. She added that, in future, the ESC will work to promote a larger representation of women in clinical trials to provide missing data on gender differences in response to drug therapy.
 Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. European Heart Journal. doi: 101093/eurheartj/ehi397.
 Gender-specific prescription for cardiovascular diseases? European Heart Journal. doi: 10.1093/eurheartj/ehi428.
Margaret Willson | alfa
3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg
Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
23.05.2018 | Life Sciences
23.05.2018 | Life Sciences
23.05.2018 | Physics and Astronomy